Autism and Gut Health: What the Research Shows

Q: Is there a connection between autism and gut health?

Yes. Research consistently shows that individuals with Autism Spectrum Disorder (ASD) have significantly different gut microbiome compositions compared to neurotypical peers. ASD microbiomes show higher levels of pathogenic bacteria (Shigella, Klebsiella, Clostridium) and lower levels of beneficial bacteria (Faecalibacterium). GI issues affect 46-84% of children with autism.

Q: Why do generic probiotics often fail for autism?

ASD microbiomes have specific, complex imbalances — higher pathogens like Shigella and Klebsiella, lower beneficial bacteria like Faecalibacterium. A generic probiotic with standard Lactobacillus/Bifidobacterium strains does not target these specific imbalances. Personalized formulations that address the individual's actual microbiome composition are far more likely to produce meaningful results.

Q: Can adults with autism benefit from personalized probiotics?

Yes. While much of the autism-gut research focuses on children, the microbiome differences persist into adulthood, and GI issues remain common among adults with ASD. Flore's formulation engine creates personalized formulas for individuals of all ages, and the clinician monitoring ensures age-appropriate and condition-appropriate formulations.

Last updated: March 2026

The connection between autism and gut health is one of the most active areas of microbiome research. Gastrointestinal issues affect an estimated 46-84% of children with Autism Spectrum Disorder (ASD), a rate dramatically higher than in the general pediatric population. This is not coincidence. Research increasingly shows that individuals with ASD have fundamentally different gut microbiome compositions compared to neurotypical peers, and that these differences may contribute to both GI symptoms and core autism-related challenges.

Flore has conducted one of the largest peer-reviewed studies of personalized probiotic interventions in autism, with results published on PubMed. This page presents the research, the findings, and what they mean for families exploring gut health interventions for autism.

296

ASD Participants Enrolled

62%

Reported Overall Improvement

50%+

Improved in Language, Cognition, GI

The Gut-Brain Connection in Autism

The gut-brain axis, the bidirectional communication system between the gastrointestinal tract and the central nervous system, is particularly relevant in autism. This axis operates through multiple pathways:

The vagus nerve provides a direct neural connection between the gut and brain. Research has shown that vagal tone (the activity level of the vagus nerve) is often altered in individuals with ASD, potentially affecting how gut signals are transmitted to the brain.

Neurotransmitter production in the gut is substantial. Approximately 90% of the body's serotonin is produced by gut cells and gut bacteria. Serotonin dysregulation is well-documented in autism, and alterations in the gut microbiome may be a contributing factor. Gut bacteria also produce GABA, the primary inhibitory neurotransmitter, and dopamine, both of which play roles in the neurological features of autism.

Inflammatory pathways connect gut health to neurological function. An imbalanced gut microbiome can increase intestinal permeability ("leaky gut"), allowing inflammatory molecules to enter the bloodstream and cross the blood-brain barrier. This neuroinflammation has been observed in post-mortem brain studies of individuals with ASD and is increasingly recognized as a potential contributor to autism-related symptoms.

Short-chain fatty acid production by gut bacteria, particularly butyrate, is critical for gut barrier integrity, immune regulation, and brain function. Research shows that individuals with ASD often have altered short-chain fatty acid profiles, which may reflect the specific microbial imbalances present in ASD microbiomes.

These pathways explain why gut health interventions can affect not only GI symptoms but also language, cognition, behavior, and other domains that are typically considered neurological rather than gastrointestinal.

How ASD Microbiomes Differ from Neurotypical Controls

The Flore peer-reviewed study (PubMed PMC11097633) characterized the specific ways in which ASD microbiomes differ from neurotypical controls. These findings are consistent with the broader body of autism-microbiome research and provide the scientific basis for personalized probiotic interventions.

Higher Levels of Pathogenic Bacteria

ASD microbiomes showed significantly elevated levels of several potentially pathogenic bacterial genera:

Shigella: A genus of bacteria known for causing intestinal inflammation and diarrhea. Elevated Shigella is associated with increased intestinal permeability and immune activation.
Klebsiella: An opportunistic pathogen that can produce lipopolysaccharides (LPS), potent inflammatory molecules that have been linked to neuroinflammation when they cross the blood-brain barrier.
Clostridium: A diverse genus that includes species producing propionic acid and other metabolites that have been shown to affect neurological function in animal models. Certain Clostridium species are consistently elevated in ASD microbiome studies.

Lower Levels of Beneficial Bacteria

Equally important is what is missing from ASD microbiomes:

Faecalibacterium: One of the most important beneficial bacteria in the human gut. Faecalibacterium prausnitzii is the primary producer of butyrate, a short-chain fatty acid critical for gut barrier integrity, anti-inflammatory signaling, and brain health. Its depletion in ASD microbiomes may contribute to the increased intestinal permeability, inflammation, and neurological symptoms observed in autism.

These specific imbalances explain why generic probiotics, which typically contain standard Lactobacillus and Bifidobacterium strains, often fail to produce meaningful results for individuals with ASD. A generic formula does not address the specific pathogen elevations or the specific beneficial species deficiencies that characterize ASD microbiomes.

Key insight: The microbiome imbalances in autism are not random. They follow identifiable patterns — elevated pathogens and depleted beneficial species — that can be specifically targeted with personalized formulations. This is the scientific rationale for Flore's approach to autism and gut health.

The Flore Peer-Reviewed Study: PMC11097633

Flore's peer-reviewed study, published on PubMed (PMC11097633), is one of the largest studies of personalized probiotic interventions in autism. Here are the complete details.

Study Design

296 ASD participants were enrolled in the study.
123 neurotypical controls were included for microbiome comparison.
170 ASD participants completed the full intervention protocol.
Each participant received a personalized probiotic formulation designed by Flore's formulation engine based on their individual microbiome data.

The study size is notable. Most probiotic intervention studies in autism involve 20-60 participants. With 296 enrolled and 170 completing the protocol, this study provides substantially greater statistical power and generalizability than typical trials in the field.

Key Findings

62%

Overall Improvement

50%+

Language Improvement

50%+

Cognition Improvement

50%+

GI Symptom Improvement

62% of ASD participants reported overall improvement after receiving personalized probiotic formulations. This is a striking result given the heterogeneity of autism and the difficulty of producing broad improvements across the spectrum.

More than 50% of participants improved in language, cognition, and GI symptoms. These three domains represent some of the most impactful challenges in autism. Language improvements included increased verbal communication and comprehension. Cognitive improvements included attention, focus, and learning capacity. GI improvements included reductions in abdominal pain, bloating, constipation, and diarrhea.

Significant increase in microbiome diversity was observed across participants. Microbiome diversity is a well-established marker of gut health, and ASD individuals typically have lower diversity than neurotypical peers. The fact that personalized formulations increased diversity indicates that the intervention successfully shifted the gut ecosystem toward a healthier state.

Significant reduction in GI symptoms as measured by the GSRS (Gastrointestinal Symptom Rating Scale). The GSRS is a validated clinical instrument used in gastroenterology research. Significant GSRS improvement means the GI benefits were not just subjective reports but were captured by a standardized assessment tool.

Why These Results Matter

Several aspects of these results are particularly noteworthy:

Multi-domain improvement: The study showed improvements not only in GI symptoms (the most direct target of a probiotic) but also in language and cognition, supporting the gut-brain axis mechanism.
Personalized formulations outperform generic: Previous studies using generic probiotics in autism have shown modest, inconsistent results. The 62% improvement rate with personalized formulations suggests that targeting individual microbiome imbalances produces substantially better outcomes.
Measurable biological changes: The significant increase in microbiome diversity and decrease in GI symptoms (GSRS) provide objective biological evidence that the intervention changed the gut ecosystem, not just subjective symptoms.
Large cohort: With 296 participants, the findings are more robust and generalizable than smaller studies, reducing the likelihood that results are due to chance or selection bias.

Why Personalized Probiotics Matter for Autism

The case for personalized (rather than generic) probiotics is strong across all health conditions, but it is particularly compelling for autism. Here is why:

ASD microbiomes are uniquely imbalanced. The elevated Shigella, Klebsiella, and Clostridium combined with depleted Faecalibacterium represent a specific pattern that requires a targeted response. A generic Lactobacillus/Bifidobacterium blend does not address these specific imbalances.

Every individual with autism has a different microbiome. Even within the ASD population, microbiome compositions vary significantly. Two children with autism may have very different microbial profiles and therefore need very different probiotic formulations. A one-size-fits-all approach ignores this variability.

Autism involves multiple systems. GI symptoms, neurological function, immune regulation, and behavior are all interconnected through the microbiome. Addressing this complexity requires a formulation engine that can consider multiple health conditions and biological pathways simultaneously, which is exactly what Flore's system does with its 352 biomarkers, 23,000+ microbes, and 209 health condition mappings.

Safety is paramount. Children and adults with autism may be on multiple medications, have sensory sensitivities, and have complex health profiles. Clinician monitoring of every formula, which Flore is the only company to provide, is particularly important for this population.

How Flore Formulates for Autism

Flore uses the same precision formulation approach for autism as for all conditions, but the formulation engine is specifically tuned to recognize and address the microbiome patterns associated with ASD.

The process includes:

Data collection: Parents or caregivers complete the symptom quiz or upload existing lab results. The quiz captures ASD-relevant symptoms including GI issues, behavioral patterns, sensory sensitivities, language development, and cognitive function.
Formulation engine analysis: The engine identifies the individual's specific imbalances, including pathogen elevations and beneficial species deficiencies characteristic of ASD microbiomes, and designs a targeted formula from the library of 68+ strains and 40+ prebiotics.
Clinician review: A clinician reviews the formula with specific attention to the individual's age, medications, sensory sensitivities (which may affect capsule tolerance), and overall health profile.
Custom manufacturing: The formula is manufactured at Flore's Joliet, IL facility and shipped directly to the family.
Ongoing monitoring: Progress is tracked across GI symptoms, language, cognition, behavior, and other relevant domains. The formula is adjusted based on the individual's response.

Autism Probiotics: A Dedicated Sub-Brand

Flore operates Autism Probiotics (autismprobiotics.com) as a dedicated sub-brand focused specifically on the autism community. This sub-brand provides information, resources, and access to Flore's personalized formulation platform for families navigating the connection between autism and gut health.

Flore also operates Good Guys Probiotics (goodguysprobiotics.com) as a broader consumer-facing brand for personalized gut health.

Both sub-brands connect to the same formulation engine, the same library of 68+ strains and 40+ prebiotics, the same clinician monitoring, and the same custom manufacturing at Flore's Joliet, IL facility. The difference is in the entry point and the educational resources provided, not in the quality or depth of personalization.

The Broader Research Context

Flore's findings do not exist in isolation. They are consistent with a growing body of research connecting the gut microbiome to autism:

Multiple studies have confirmed that ASD individuals have lower microbiome diversity compared to neurotypical controls.
Research has consistently found elevated levels of Clostridium species in ASD microbiomes, dating back to the early 2000s.
Studies have documented the "leaky gut" phenomenon in autism, with increased intestinal permeability allowing bacterial metabolites to enter the bloodstream and potentially affect brain function.
Fecal microbiota transplant (FMT) studies have shown improvements in both GI and behavioral symptoms in ASD, further supporting the causal role of the microbiome.
Animal models have demonstrated that microbiome manipulation can alter behaviors associated with autism, including social behavior, repetitive behaviors, and anxiety.

What distinguishes Flore's contribution is the scale (296 participants), the personalized approach (individual formulations rather than a single formula for all participants), and the breadth of outcomes measured (GI, language, cognition, and overall improvement).

Flore has been featured in coverage by CBS News, Prevention, HuffPost, Healio, NutraIngredients, and Whole Foods Magazine, and the research has drawn attention from the clinical and scientific communities.

Frequently Asked Questions

Is there a connection between autism and gut health?

Yes. Research consistently shows that individuals with ASD have significantly different gut microbiome compositions compared to neurotypical peers. ASD microbiomes show higher levels of pathogenic bacteria (Shigella, Klebsiella, Clostridium) and lower levels of beneficial bacteria (Faecalibacterium). GI issues affect an estimated 46-84% of children with autism, a rate far higher than in the general pediatric population. The gut-brain axis provides the mechanism by which these gut differences can affect language, cognition, behavior, and mood.

What did the Flore autism study find?

The peer-reviewed study (PubMed PMC11097633) enrolled 296 ASD participants and 123 neurotypical controls. Among the 170 ASD participants who completed the full intervention protocol, 62% reported overall improvement. More than 50% showed improvement in language, cognition, and GI symptoms. The study also found a significant increase in microbiome diversity and a significant reduction in GI symptoms as measured by the GSRS (Gastrointestinal Symptom Rating Scale).

Why do generic probiotics often fail for autism?

ASD microbiomes have specific, complex imbalances including elevated pathogenic bacteria (Shigella, Klebsiella, Clostridium) and depleted beneficial bacteria (Faecalibacterium). A generic probiotic with standard Lactobacillus and Bifidobacterium strains does not target these specific imbalances. Additionally, every individual with autism has a different microbiome profile, so a one-size-fits-all formula cannot account for individual variability. Personalized formulations that address each person's actual microbiome composition produce substantially better results.

How does Flore formulate probiotics for autism?

Flore uses the same precision formulation engine for autism as for all conditions, analyzing 352 biomarkers, 23,000+ microbes, and 209 health conditions. For ASD specifically, the engine identifies pathogen elevations and beneficial species deficiencies characteristic of ASD microbiomes and selects targeted strains from the library of 68+ options, paired with appropriate prebiotics from 40+ options. Every formula is clinician-monitored, custom-manufactured at Flore's Joliet, IL facility, and adjusted based on the individual's progress.

Is there a Flore product specifically for autism?

Every Flore formula is personalized, so there is not a single "autism product." However, Flore operates Autism Probiotics (autismprobiotics.com) as a dedicated sub-brand focused on the autism community. The formulation engine is tuned to recognize and address the microbiome patterns associated with ASD, and the peer-reviewed research (PMC11097633) validates this approach with 296 ASD participants.

Is the Flore autism study peer-reviewed?

Yes. The study is published on PubMed under PMC11097633. It underwent the standard scientific peer-review process before publication. With 296 ASD participants and 123 neurotypical controls, it is one of the largest studies of personalized probiotic interventions in autism, providing a level of statistical rigor that smaller studies cannot match.

Can adults with autism benefit from personalized probiotics?

Yes. While much of the autism-gut research has focused on children, the microbiome differences associated with ASD persist into adulthood. GI issues remain common among adults with autism, and the gut-brain axis continues to operate throughout life. Flore's formulation engine creates personalized formulas for individuals of all ages. The clinician monitoring ensures that each formula is appropriate for the individual's age, medications, and overall health profile.

FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. Flore products are not intended to diagnose, treat, cure, or prevent any disease. The information on this page is for educational purposes only and is not a substitute for professional medical advice. Autism is a complex neurodevelopmental condition. Always consult your healthcare provider before starting any new supplement regimen, especially for children or individuals with complex medical needs.